The effects of caloric restriction on Fetuin-A and cardiovascular risk factors in rats and humans

A randomized controlled trial

Kyung Mook Choi, Kyung Ah Han, Hee Jung Ahn, So Young Lee, Soon Young Hwang, Baek-Hui Kim, Ho Cheol Hong, Hae Yoon Choi, Sae Jeong Yang, Hye-Jin Yoo, Sei-Hyun Baik, Dong Seop Choi, Kyung Wan Min

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objectives The liver-secreted protein fetuin-A is associated with insulin resistance, metabolic syndrome, type 2 diabetes and atherosclerosis. We examined the effect of caloric restriction (CR) on fetuin-A levels and concomitant changes in hepatic steatosis and cardiovascular risk factors in rats and humans. Design and Subjects We performed a randomized, controlled clinical trial to examine circulating fetuin-A levels and cardiovascular risk parameters including visceral fat area (VFA), atherogenic lipid profile, inflammatory markers, adipokines levels and brachial artery endothelial function in 76 overweight women with type 2 diabetes before and after 12 weeks of CR. In addition, the effects of CR on hepatic steatosis and fetuin-A mRNA expression were evaluated in Otuska Long Evans Tokushima Fatty (OLETF) rats, an animal model of obesity and type 2 diabetes. Results Circulating fetuin-A levels were significantly decreased after 12 weeks of CR and were accompanied by improvements in VFA, blood pressure, glucose, lipid profiles and liver function. The CR group also showed a significant decrease in apolipoprotein B, leptin and insulin resistance compared to those in the control group, although endothelial function was not different. Multiple regression analysis showed that the changes in fetuin-A levels were independently associated with CR and changes in hsCRP and adiponectin (R2 = 0·156). Moreover, CR significantly reduced hepatic steatosis and fetuin-A expression, as well as weight, glucose, total cholesterol and triglyceride levels, in OLETF rats. Conclusion Caloric restriction significantly reduced the hepatic expression of fetuin-A and its circulating levels and improved several cardiovascular risk factors in obese rats and humans with type 2 diabetes.

Original languageEnglish
Pages (from-to)356-363
Number of pages8
JournalClinical Endocrinology
Volume79
Issue number3
DOIs
Publication statusPublished - 2013 Sep 1

Fingerprint

alpha-2-HS-Glycoprotein
Caloric Restriction
Randomized Controlled Trials
Type 2 Diabetes Mellitus
Liver
Intra-Abdominal Fat
Insulin Resistance
Lipids
Adipokines
Brachial Artery
Adiponectin
Apolipoproteins B
Leptin
Blood Glucose
Atherosclerosis
Triglycerides
Animal Models
Obesity
Cholesterol
Regression Analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

The effects of caloric restriction on Fetuin-A and cardiovascular risk factors in rats and humans : A randomized controlled trial. / Choi, Kyung Mook; Han, Kyung Ah; Ahn, Hee Jung; Lee, So Young; Hwang, Soon Young; Kim, Baek-Hui; Hong, Ho Cheol; Choi, Hae Yoon; Yang, Sae Jeong; Yoo, Hye-Jin; Baik, Sei-Hyun; Choi, Dong Seop; Min, Kyung Wan.

In: Clinical Endocrinology, Vol. 79, No. 3, 01.09.2013, p. 356-363.

Research output: Contribution to journalArticle

Choi, Kyung Mook ; Han, Kyung Ah ; Ahn, Hee Jung ; Lee, So Young ; Hwang, Soon Young ; Kim, Baek-Hui ; Hong, Ho Cheol ; Choi, Hae Yoon ; Yang, Sae Jeong ; Yoo, Hye-Jin ; Baik, Sei-Hyun ; Choi, Dong Seop ; Min, Kyung Wan. / The effects of caloric restriction on Fetuin-A and cardiovascular risk factors in rats and humans : A randomized controlled trial. In: Clinical Endocrinology. 2013 ; Vol. 79, No. 3. pp. 356-363.
@article{889a58c216dd44d9b8d32a127f7f171a,
title = "The effects of caloric restriction on Fetuin-A and cardiovascular risk factors in rats and humans: A randomized controlled trial",
abstract = "Objectives The liver-secreted protein fetuin-A is associated with insulin resistance, metabolic syndrome, type 2 diabetes and atherosclerosis. We examined the effect of caloric restriction (CR) on fetuin-A levels and concomitant changes in hepatic steatosis and cardiovascular risk factors in rats and humans. Design and Subjects We performed a randomized, controlled clinical trial to examine circulating fetuin-A levels and cardiovascular risk parameters including visceral fat area (VFA), atherogenic lipid profile, inflammatory markers, adipokines levels and brachial artery endothelial function in 76 overweight women with type 2 diabetes before and after 12 weeks of CR. In addition, the effects of CR on hepatic steatosis and fetuin-A mRNA expression were evaluated in Otuska Long Evans Tokushima Fatty (OLETF) rats, an animal model of obesity and type 2 diabetes. Results Circulating fetuin-A levels were significantly decreased after 12 weeks of CR and were accompanied by improvements in VFA, blood pressure, glucose, lipid profiles and liver function. The CR group also showed a significant decrease in apolipoprotein B, leptin and insulin resistance compared to those in the control group, although endothelial function was not different. Multiple regression analysis showed that the changes in fetuin-A levels were independently associated with CR and changes in hsCRP and adiponectin (R2 = 0·156). Moreover, CR significantly reduced hepatic steatosis and fetuin-A expression, as well as weight, glucose, total cholesterol and triglyceride levels, in OLETF rats. Conclusion Caloric restriction significantly reduced the hepatic expression of fetuin-A and its circulating levels and improved several cardiovascular risk factors in obese rats and humans with type 2 diabetes.",
author = "Choi, {Kyung Mook} and Han, {Kyung Ah} and Ahn, {Hee Jung} and Lee, {So Young} and Hwang, {Soon Young} and Baek-Hui Kim and Hong, {Ho Cheol} and Choi, {Hae Yoon} and Yang, {Sae Jeong} and Hye-Jin Yoo and Sei-Hyun Baik and Choi, {Dong Seop} and Min, {Kyung Wan}",
year = "2013",
month = "9",
day = "1",
doi = "10.1111/cen.12076",
language = "English",
volume = "79",
pages = "356--363",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The effects of caloric restriction on Fetuin-A and cardiovascular risk factors in rats and humans

T2 - A randomized controlled trial

AU - Choi, Kyung Mook

AU - Han, Kyung Ah

AU - Ahn, Hee Jung

AU - Lee, So Young

AU - Hwang, Soon Young

AU - Kim, Baek-Hui

AU - Hong, Ho Cheol

AU - Choi, Hae Yoon

AU - Yang, Sae Jeong

AU - Yoo, Hye-Jin

AU - Baik, Sei-Hyun

AU - Choi, Dong Seop

AU - Min, Kyung Wan

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Objectives The liver-secreted protein fetuin-A is associated with insulin resistance, metabolic syndrome, type 2 diabetes and atherosclerosis. We examined the effect of caloric restriction (CR) on fetuin-A levels and concomitant changes in hepatic steatosis and cardiovascular risk factors in rats and humans. Design and Subjects We performed a randomized, controlled clinical trial to examine circulating fetuin-A levels and cardiovascular risk parameters including visceral fat area (VFA), atherogenic lipid profile, inflammatory markers, adipokines levels and brachial artery endothelial function in 76 overweight women with type 2 diabetes before and after 12 weeks of CR. In addition, the effects of CR on hepatic steatosis and fetuin-A mRNA expression were evaluated in Otuska Long Evans Tokushima Fatty (OLETF) rats, an animal model of obesity and type 2 diabetes. Results Circulating fetuin-A levels were significantly decreased after 12 weeks of CR and were accompanied by improvements in VFA, blood pressure, glucose, lipid profiles and liver function. The CR group also showed a significant decrease in apolipoprotein B, leptin and insulin resistance compared to those in the control group, although endothelial function was not different. Multiple regression analysis showed that the changes in fetuin-A levels were independently associated with CR and changes in hsCRP and adiponectin (R2 = 0·156). Moreover, CR significantly reduced hepatic steatosis and fetuin-A expression, as well as weight, glucose, total cholesterol and triglyceride levels, in OLETF rats. Conclusion Caloric restriction significantly reduced the hepatic expression of fetuin-A and its circulating levels and improved several cardiovascular risk factors in obese rats and humans with type 2 diabetes.

AB - Objectives The liver-secreted protein fetuin-A is associated with insulin resistance, metabolic syndrome, type 2 diabetes and atherosclerosis. We examined the effect of caloric restriction (CR) on fetuin-A levels and concomitant changes in hepatic steatosis and cardiovascular risk factors in rats and humans. Design and Subjects We performed a randomized, controlled clinical trial to examine circulating fetuin-A levels and cardiovascular risk parameters including visceral fat area (VFA), atherogenic lipid profile, inflammatory markers, adipokines levels and brachial artery endothelial function in 76 overweight women with type 2 diabetes before and after 12 weeks of CR. In addition, the effects of CR on hepatic steatosis and fetuin-A mRNA expression were evaluated in Otuska Long Evans Tokushima Fatty (OLETF) rats, an animal model of obesity and type 2 diabetes. Results Circulating fetuin-A levels were significantly decreased after 12 weeks of CR and were accompanied by improvements in VFA, blood pressure, glucose, lipid profiles and liver function. The CR group also showed a significant decrease in apolipoprotein B, leptin and insulin resistance compared to those in the control group, although endothelial function was not different. Multiple regression analysis showed that the changes in fetuin-A levels were independently associated with CR and changes in hsCRP and adiponectin (R2 = 0·156). Moreover, CR significantly reduced hepatic steatosis and fetuin-A expression, as well as weight, glucose, total cholesterol and triglyceride levels, in OLETF rats. Conclusion Caloric restriction significantly reduced the hepatic expression of fetuin-A and its circulating levels and improved several cardiovascular risk factors in obese rats and humans with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84880825239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880825239&partnerID=8YFLogxK

U2 - 10.1111/cen.12076

DO - 10.1111/cen.12076

M3 - Article

VL - 79

SP - 356

EP - 363

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 3

ER -